How FDA aims to support generic opioids
March 28th 2016FDA issued a draft guidance to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF), while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug.
Read More
Successful payer-provider collaborations: 4 characteristics
March 28th 2016While value-based reimbursement presents opportunities for payers and providers, succeeding in such a reimbursement model can be challenging. Here are four things to strive for that could increase the likelihood of success in a value-based reimbursement model.
Read More
FDA requires warning on opioids
March 22nd 2016A month after FDA announced several measures aimed at curbing opioid abuse, the agency said it would require a new boxed warning addressing the serious risk of misuse, abuse, addiction, overdose and death on immediate-release (IR) opioid pain medications.
Read More
Six steps for health plans when launching new products
March 22nd 2016With the tremendous amount of innovation occurring in all aspects of the healthcare industry, the opportunity to transition innovations into successful, impactful products that improve patient care and member experience has never been greater. Here are six tips.
Read More
Brand and specialty drug spending spikes
March 21st 2016Spending on brand name drugs spiked 16.2% in 2015 and 98.2% since 2011, according to a new report from pharmacy benefit manager (PBM) Express Scripts. Plus, a third of branded products experienced price increases greater than 20% in 2015, according to Express Scripts’ annual Drug Trend Report.
Read More
Supreme Court Zubik v. Burwell: Industry implications
March 21st 2016The court will consider whether an “accommodation” allowing nonprofit religiously-affiliated organizations to opt out of the ACA requirement that insurance plans include contraception coverage is consistent with the Religious Freedom Restoration Act (RFRA).
Read More